Aclaris Therapeutics, Inc. Total Long-Term Debt
Aclaris Therapeutics, Inc. (ACRS) had Total Long-Term Debt of $10.73 million as of 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Balance Sheet › Liabilities › Debt
us-gaap:LongTermDebt · last filed 2022-02-24
- 2021-06-30: Long-term Debt $10.73M.
- 2021-03-31: Long-term Debt $10.69M.
- 2020-12-31: Long-term Debt $10.65M.
- 2020-09-30: Long-term Debt $10.61M.
| Period end | Long-term Debt |
|---|---|
| 2021-06-30 | $10.73M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $10.69M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $10.65M 10-K · filed 2022-02-24 |
| 2020-09-30 | $10.61M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $10.57M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $10.57M 10-Q · filed 2020-05-07 |
| 2019-09-30 | $29.93M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $29.92M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $29.92M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $29.91M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |